About Us

Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

A Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Social Media

Bluesky • Facebook • Instagram • LinkedIn • YouTube

Meet the Laser Focus World Team

Editorial

Sales

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology
My Watchlist
Indicators
Industrial Laser Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Renowned ALS Researcher Confirms The Efficacy Of NeuroSense Therapeutics’ Lead Drug Candidate, PrimeC

By: ACCESSWIRE

HERZLIYA, ISRAEL / ACCESSWIRE / October 19, 2023 / Induced pluripotent stem cells (iPSCs) have emerged as a promising tool in the field of research and therapy for neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS). ALS is a progressive disorder that affects motor neurons, leading to muscle weakness, paralysis and ultimately death. iPSCs are adult cells that have been reprogrammed to behave like embryonic stem cells, capable of differentiating into various cell types. By generating iPSCs from people living with ALS, researchers are able to study disease-specific cellular pathologies and gain insights into the underlying mechanisms of the disease.

One of the major advantages of using iPSCs in ALS research is the potential to model disease progression and test potential therapeutics in a laboratory setting. iPSCs can be differentiated into motor neurons - the key cells affected in ALS - allowing researchers to study the dysfunction and degeneration of these cells. By comparing iPSC-derived motor neurons from ALS patients to healthy controls, scientists can identify disease-associated changes, such as altered gene expression or protein levels. This can help in the development of biomarkers for early detection and monitoring of ALS progression, as well as provide targets for potential drug development.

One company that is exploring the relationship between iPSCs and ALS is NeuroSense Therapeutics (NASDAQ: NRSN). NeuroSense Therapeutics is a cutting-edge biotechnology company that develops a novel combination therapy aimed to address several mechanisms in this complex disease. NeuroSense, in a collaboration with the University of Southern California (USC), utilized iPSCs to advance the understanding of ALS by studying disease-specific cellular models derived from iPSCs.

PrimeC is specifically designed to treat ALS by modulating microRNA synthesis, reducing neuroinflammation and impacting iron accumulation. This innovative formulation combines meticulously calibrated doses of two FDA-approved drugs, Ciprofloxacin and Celecoxib, with the goal of synergistically inhibiting the advancement of ALS. PrimeC effectively attenuates motor neuron degeneration and suppresses inflammatory responses, surpassing the performance of traditional ALS treatments in studies conducted using a zebrafish model.

The company made an important announcement early this month about its latest development in treating neurodegenerative diseases. An independent study led by Dr. Justin Ichida at USC focused on ALS. Dr. Ichida is a respected expert in stem cell biology and regenerative medicine, known for his innovative research for finding treatments for ALS and Alzheimer's disease. He's regarded as a leader in using iPSCs, a cutting-edge cellular technique, for drug testing and development.

"Dr. Ichida has been described as being beyond the cutting edge in his field and we are honored that he and his lab chose to evaluate PrimeC in this non-sponsored study," shared NeuroSense Founder and CEO Alon Ben Noon. "These results further bolster our confidence that PrimeC may offer a much-needed therapy for this debilitating disease which is ALS. We are proud that PrimeC is recognized as a leading ALS drug candidate by the top medical institutions in the world."

In the study, Dr. Ichida used iPSCs derived from blood samples of ALS patients. The goal was to test the effect of NeuroSense's treatment, PrimeC, on induced motor neurons. The results demonstrated that PrimeC had a significant positive impact on the survival rate of the motor neurons compared to each component alone. This shows the value of combining the two components in NeuroSense's formulation. In addition, according to a previous independent study conducted by Dr. Ichida, PrimeC was among the best molecules that were tested, including two FDA-approved drugs for ALS, as the results were comparable to a healthy control. (see chart below).

"At our lab, we screen thousands of compounds in search of one that may be effective in ALS, and we were very impressed by the data resulting from our iPCS in vitro study of PrimeC. We chose to evaluate PrimeC based on the growing body of clinical, pre-clinical, and biomarker data on its efficacy in ALS," said Dr. Ichida. "As a candidate compound, NeuroSense's combination was among the best in improving motor neuron survival. Furthermore, in a follow-on study, where we explored specifically the synergistic effect of PrimeC combination relative to each one of its therapeutic agents, the results exceeded our expectations, as PrimeC increased the survival rate to the level of the healthy control and that got us very excited."

This latest study is a significant development for NeuroSense. It provides further evidence of the potential effectiveness of its treatment, PrimeC, in addressing ALS, which is a major breakthrough for the company. NeuroSense is expecting to announce clinical topline results from its phase 2b ALS study in several weeks.

Featured photo by Rattiya Thongdumhyu on Shutterstock.

Contact:

IR: Corporate Profile - Dilek Mir
dmir@corporateprofile.com

SOURCE: NeuroSense Therapeutics Ltd



View source version on accesswire.com:
https://www.accesswire.com/794636/renowned-als-researcher-confirms-the-efficacy-of-neurosense-therapeutics-lead-drug-candidate-primec

More News

View More
Lower Rates Put RV Stocks Back in the Fast Lane
Via MarketBeat
Tickers CWH THO WGO
Alphabet: Time to Take Profits, Buy, or Wait for a Pullback?
Via MarketBeat
Topics Artificial Intelligence
Tickers GOOGL
Hershey vs. Mondelez: Which Stock Wins Chocolate Season?
Via MarketBeat
Topics Economy
Tickers HSY MDLZ PEP
Thor Industries Tracking for New Highs in 2026
Via MarketBeat
Topics Economy
Tickers THO
Cintas Stock Sends a Clear Buy Signal as Momentum Builds
Via MarketBeat
Topics Government
Tickers CTAS
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.